Corvus Pharmaceuticals
CRVS
31 hedge funds and large institutions have $229M invested in Corvus Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 31 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$75.4M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$45.3M |
| 3 |
ASP
Adams Street Partners
Chicago,
Illinois
|
+$38.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.5M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.11M |
Top Sellers
CRVS Hedge Fund Activity: Q1 2016 in Review
31 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q1 2016, worth a combined $229M.
Buyers outnumbered sellers: 31 funds opened new CRVS positions and 0 closed out — a net gain of 31 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $75.4M.
- 31 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q1 2016, up from 0 in Q4 2015.
- Funds reported $229M of Corvus Pharmaceuticals stock for Q1 2016.
- 31 funds opened new Corvus Pharmaceuticals positions in Q1 2016 and 0 closed out, a net change of +31 holders.
- The largest Corvus Pharmaceuticals buyer in Q1 2016 was OrbiMed, an estimated $75.4M added.
Based on aggregated 13F filings for Q1 2016.